Menu

Market-Moving News for September 22nd

Benzinga Newsdesk 1 year ago

MoversTrading Ideas

MBX: 46% | MBX Biosciences shares are trading higher after the company announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic

Read the original